With a unique approach, Eligo engineers natural predators of bacteria to deliver CRISPR systems that kill antibiotic-resistant superbugs in the gut microbiome. CARB-X announced…
Big Pharma exited from the antibiotics space one by one – and now they may be coming back together Pfizer, Eli Lilly, Novo Nordisk,…
Access to surveillance data crucial to tackling infectious diseases Wellcome Trust has partnered with Pfizer Inc. and the governments of Ghana, Kenya, Malawi and…
CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience, Brisbane, Australia, to develop a new class of…
CARB-X will invest up to $3m into India-based diagnostics company Module Innovations whichis developing a rapid easy-to-use diagnostic for drug-resistant urinary tract infections (UTI).…
The June issue of ACS Infectious Diseases is a special issue on antibiotics featuring all major stakeholders and perspectives in the AMR community. The…
GARD is looking for a new Board member with high-level executive experience and strategy setting in pharmaceutical/biotech industry. Applications and nominations will be accepted…
Until 31 July 2020 companies developing new treatments to combat AMR are invited to submit proposals. Today, the Novo Holdings REPAIR Impact Fund announced…